InflaRx N.V. (IF0.F)
| Previous close | 1.2010 |
| Open | 1.2880 |
| Bid | 1.2880 x 0 |
| Ask | 1.3270 x 0 |
| Day's range | 1.2880 - 1.2880 |
| 52-week range | 1.1020 - 4.8250 |
| Volume | |
| Avg. volume | 1,130 |
| Market cap | 81.986M |
| Beta (5Y monthly) | 1.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7800 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.28 |
GlobeNewswireInflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City. InflaRx will participate in a panel titled, New Potential Dermatology Treatments for Psoriasis, Urticaria, and Alopecia scheduled on May 14, 2024, at 2:30 PM EDT /
ZacksInflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
InflaRx (IFRX) delivered earnings and revenue surprises of -50% and 99.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Globe NewswireInflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor INF904 INF904 development will be initially targeted at chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), with initiation of a Phase IIa PK dose-ranging study expected by the end of 2024, with data availability anticipated in 2025 InflaRx is considering partnership options for
